Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.
2.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

3.

[Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan].

Mera T, Saijo N, Akaza H.

Gan To Kagaku Ryoho. 2012 Apr;39(4):551-62. Japanese.

PMID:
22504677
4.

Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.

Sarkar D, Singh SK, Mandal AK, Agarwal MM, Mete UK, Kumar S, Mavuduru RS, Prasad R.

Cancer Biomark. 2010-2011;8(2):81-7. doi: 10.3233/CBM-2011-0198.

PMID:
21896995
5.

Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.

Takaha N, Okihara K, Kamoi K, Hongo F, Iwata T, Yano K, Ueda T, Takeuchi I, Yamada T, Kawauchi A, Miki T.

Urol Int. 2011;87(3):263-9. doi: 10.1159/000328217. Epub 2011 Aug 26.

PMID:
21876321
6.

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.

Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.

BJU Int. 2010 Oct;106(7):974-8. doi: 10.1111/j.1464-410X.2010.09296.x. Epub 2010 Mar 9.

7.

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Chauchereau A, Fizazi K.

Eur J Cancer. 2010 Jul;46(10):1770-2. doi: 10.1016/j.ejca.2010.04.010. Epub 2010 May 17.

PMID:
20483588
8.

Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.

Arsov C, Winter C, Rabenalt R, Albers P.

Urol Oncol. 2012 Nov-Dec;30(6):762-71. doi: 10.1016/j.urolonc.2010.02.001. Epub 2010 Sep 29. Review.

PMID:
20884252
9.

[Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer].

Park SC, Whan LJ, Sik RJ.

Actas Urol Esp. 2012 Jul-Aug;36(7):425-30. doi: 10.1016/j.acuro.2011.09.008. Epub 2012 Mar 3. Spanish.

PMID:
22386299
10.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
11.

Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.

Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.

Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Erratum in: Cancer Chemother Pharmacol. 2011 Jun;67(6):1463.

PMID:
21365219
12.

[Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel].

Saitou Y, Hatanaka Y, Imanishi M, Ohzeki T, Hashimoto K, Sugimoto K, Esa A, Kajikawa H, Yasuda M, Yamamoto Y, Uemura H.

Hinyokika Kiyo. 2012 Jan;58(1):7-11. Japanese.

13.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
14.

PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.

Nelius T, Filleur S.

Prostate. 2009 Dec 1;69(16):1802-7. doi: 10.1002/pros.21024. Review.

PMID:
19676083
15.

Cabazitaxel for the treatment of prostate cancer.

Michielsen DP, Braeckman JG, Denis L.

Expert Opin Pharmacother. 2011 Apr;12(6):977-82. doi: 10.1517/14656566.2011.567268. Epub 2011 Mar 15. Review.

PMID:
21406025
16.

Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.

Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G.

BJU Int. 2011 Jan;107(2):234-9. doi: 10.1111/j.1464-410X.2010.09498.x.

17.

Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.

Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A, Itoh K.

Prostate. 2012 Jun 1;72(8):834-45. doi: 10.1002/pros.21485. Epub 2011 Sep 19.

PMID:
21932426
18.

Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.

Sella A, Sternberg CN, Skoneczna I, Kovel S.

BJU Int. 2008 Dec;102(11):1607-9. doi: 10.1111/j.1464-410X.2008.07873.x. Epub 2008 Oct 2.

19.

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.

Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R.

BJU Int. 2013 Jan;111(1):44-52. doi: 10.1111/j.1464-410X.2012.11404.x. Epub 2012 Aug 29.

20.

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.

Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6.

Supplemental Content

Support Center